Cleansing Prospectus
Released
Released
Announcement PDF
Prospectus
ELIXINOL WELLNESS LIMITED
ACN 621 479 794
(ASX code: EXL)
An offer by the Company of up to 100,000 New Shares at an issue price of $0.1 per New Share to
raise up to $10,000.
This Prospectus is prepared in accordance with Section 708A(11)(2)(b) of the Corporations Act for
the purpose of removing trading restrictions on the sale of any Shares issued pursuant to the Offer
and any Shares issued by the Company on or prior to the date of this Prospectus.
NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES
AN INVESTMENT IN THE COMPANY'S SECURITIES SHOULD BE CONSIDERED
SPECULATIVE
This Prospectus is an important document and should be read in its entirety. It is a prospectus
issued pursuant to Section 713 of the Corporations Act. It does not, itself, contain all the
information that is generally required to be set out in a full prospectus, but refers to other
documents, the information of which is deemed to be incorporated into this prospectus. The
securities offered by this Prospectus should be considered speculative.
Signed on behalf of Elixinol Wellness Limited in accordance
with section 351 of the Corporations Act 2001 (Cth):
............................................................................................
Signature of director
David Fenlon
............................................................................................
Name
4 June 2025
............................................................................................
Date
2
IMPORTANT INFORMATION
This Prospectus is issued by Elixinol Wellness
Limited ACN 621 479 794 dated 4 June 2025 and
was lodged with ASIC on that date. Neither ASIC
nor ASX or any of their officers, take any
responsibility for the contents of this Prospectus.
in, the United States in accordance with an
available exemption from registration.
The contents of this Prospectus have not been
reviewed by any regulatory authority in Hong Kong
nor is any offer under this Prospectus to be made
to persons or entities resident in Hong Kong. This
Prospectus has not been registered as a
prospectus with the Monetary Authority of
Singapore.
No securities will be issued on the basis of this
Prospectus later than 13 months after the date of
this Prospectus.
In preparing this Prospectus, regard has been had
to the fact that ASX maintains a database of
publicly disclosed information about the Company,
that the Company is a disclosing entity for the
purposes of the Corporations Act and that certain
matters may reasonably be expected to be known
to professional advisors with whom potential
investors may consult. This Prospectus has been
prepared pursuant to Section 713 of the
Corporations Act, which allows the issue of a more
concise prospectus in relation to an offer of
continuously quoted securities. It is intended to be
read in conjunction with publicly available
information, as described in Section 5.1 below.
No person is authorised to give any information or
to make any representation in connection with the
Offer that is not contained in this Prospectus. Any
information or representation not contained in this
Prospectus may not be relied upon as having been
authorised by the Company in connection with the
Offer. Neither the Company nor any other person
warrants the future performance of the Company or
any return on any investment made under this
Prospectus except as required by law and then
only to the extent so required.
This Prospectus does not take into account the
investment objectives, financial situation and
particular needs of any person. Professional
advice should be sought before deciding to invest
in any securities the subject of this Prospectus.
Various statements in this Prospectus constitute
statements relating to intentions, future acts and
events. Such statements are generally classified
as forward looking statements and involve known
and unknown risks, uncertainties and other
important factors that could cause those future
acts, events and circumstances to differ from the
way or manner in which they are expressly or
implicitly portrayed in this Prospectus.
There are risks associated with an investment in
the Company and the securities offered under this
Prospectus should be regarded as a speculative
investment. The securities offered under this
Prospectus carry no guarantee with respect to
return on capital investment, payment of dividends
or the future value of the New Shares.
The Offer does not, and is not intended to,
constitute an offer in any place or jurisdiction in
which, or to any person to whom, it would not be
lawful to make such an offer or to issue this
document under the laws applicable in that
jurisdiction.
Certain abbreviations and other defined terms are
used throughout this Prospectus. Details of the
definitions and abbreviations used are set out in
Section 6 of this Prospectus.
All financial
amounts shown in this Prospectus are expressed
in Australian dollars unless otherwise stated.
The distribution of this Prospectus in jurisdictions
outside Australia and New Zealand may be
restricted by law and any person into whose
possession this Prospectus comes should seek
advice on and observe any such restrictions. Any
failure to comply with such restrictions may
constitute a violation of applicable securities laws.
No action has been taken to lodge this Prospectus
in any jurisdiction outside of Australia or to
otherwise permit a public offering of New Shares in
any jurisdiction outside Australia.
This Prospectus may be viewed in electronic form
online
at
the
Company's
website
elixinolwellness.com. The information on the
Company's website (outside the electronic
Prospectus) does not form part of this Prospectus.
Additional copies of the Prospectus are available at
the registered office of the Company.
Any person may obtain a copy of this Prospectus
or any of the documents referred to in Section 5.1
free of charge by contacting the Company
Secretary via email on: tony.pietro@vistra.com.
The New Shares have not been and will not be
registered under the US Securities Act of 1933 and
may only be offered, sold or resold in, or to persons
2
3
SUMMARY OF THE OFFER
Topic
Details
More
information
What is the Offer?
This Prospectus relates to the Offer to be made by the Company
of up to 100,000 Shares at an issue price of $0.1 per Share to
raise up to $10,000 (before issue costs).
Section 2
What is the purpose of This Prospectus has been prepared in accordance with Section
the Prospectus
708A(11)(2)(b) of the Corporations Act for the purpose of
removing trading restrictions on the sale of any Shares issued
pursuant to the Offer or issued on or prior to the date of this
Prospectus.
Section 2
Nature
of
Prospectus
Section 1.2
this This Prospectus is a transaction specific prospectus issued under
section 713 of the Corporations Act relating to securities of a
class which have been quoted for 12 months before the date of
this Prospectus.
Application for Shares Applications for Shares under the Offer must only be made by
those persons personally invited to accept the Offer.
-
An application for Shares can only be made by an invited investor
using an Application Form. A completed Application Form and
accompanying cheque must be mailed or delivered to the
Company as follows:
The Company Secretary
Elixinol Wellness Limited
Suite 2, Level 11, 385 Bourke Street
Melbourne, VIC 3000
Opening and Closing
Dates
The Opening Date is 5 June 2025 and the Closing Date is 5.00
pm (AEST) 30 June 2025. The Company reserves the right to
close the Offer early.
Section 2
Risk Factors
Refer to Section 3.
Section 3
Minimum raising
There is no minimum raising under this Prospectus.
How do the New
Shares rank
ASX
All New Shares issued will rank equally in all respects with
existing Shares from the date of their issue.
The Company is admitted to the Official List of the ASX. Not later
than 7 days after the date of this Prospectus, the Company
intends to make an application to the ASX for the Official
Quotation of the Shares offered under this Prospectus. The fact
that the ASX may admit the Shares for Official Quotation is not to
be taken in any way as an indication of the value or merits of the
Company or of the Shares offered under this Prospectus.
Official Quotation, if granted, will commence as soon as
practicable after the issue of transaction holding Statements to
successful Applicants in respect of the Shares. If permission for
quotation of the Shares offered under this Prospectus is not
granted within 3 months after the date of this Prospectus, all
Application money will be refunded without interest.
Section 4.3
4
1.
Overview
1.1
Introduction
This Prospectus relates to the Offer to be made by the Company of up to 100,000 New Shares at
an issue price of $0.1 per New Share to raise up to $10,000 (before the costs of the issue).
The opening date of the Offer is 5 June 2025 (Opening Date) and the closing date of the Offer is
5.00 pm (AEST) 30 June 2025 (Closing Date). The Company reserves the right to close the Offer
early without notice.
The Offer is not underwritten and there is no sponsoring broker.
The Company is already included in the Official List of the ASX and the ASX Listing Rules apply to
all securities issued by the Company.
1.2
Purpose of this Prospectus
The primary purpose of the Offer is to remove the trading restrictions on the sale of any Shares
issued pursuant to the Offer and any Shares that have been issued on or prior to the date of this
Prospectus, in each case in accordance with Section 708A(11) of the Corporations Act.
As noted in the Company's ASX announcement of 21 May 2025, the Company has agreed to issued
8,571,429 fully paid ordinary shares in the capital of the Company at $0.0175 per Share to raise
$150,000 (Placement) however at the time of issue the Company will not be able to lodge a section
708A(5) cleansing notice as the Company's Shares have been subject to suspension from trading
for 6 trading days in the last 12 consecutive calendar months.
Those Shares the subject of the Placement have not been traded and the issue of this Prospectus
will cleanse the Shares issued under the Placement on 28 May 2025 plus any Shares issued under
this Prospectus.
The Company is seeking to raise only a nominal amount of $10,000 under this Prospectus and,
accordingly, the purpose of this Prospectus is not to raise capital. These funds will be put towards
the costs of the Offer.
1.3
Applications
Applications for Shares under the Offer must be made using an Application Form and are made on
the conditions stated in the Application Form.
The Directors reserve the right to issue Shares pursuant to the Offer at their absolute discretion.
Accordingly, please do not submit an Application Form unless directed to do so by the Directors.
5
2.
Effect of the Offer on the Company
2.1
Effect on financial position of the Company
The effect on the financial position of the Company by a full subscription for all the New Shares
pursuant to the Offer (Fully Subscribed) will be to increase the Company's cash reserves by
$10,000 (prior to the expenses of this Offer).
It is estimated that the expenses of this Offer will amount to approximately $10,000, leaving a $nil
net effect of the Offer upon the cash reserves of if the Company proceeds with the allotment of the
maximum number of new shares detailed in this Prospectus.
2.2
(a)
Effect on the capital structure of the Company
Details of Capital Structure
The following table sets out the existing capital structure of the Company as at 4 June 2025.
For the purposes of presenting this table, the below table assumes that prior to the Closing Date
there will be no other Share issues by the Company and that there will be no securities convertible
into Shares issued and converted prior to the Closing Date.
Share Capital Structure
Number on issue
Shares currently on issue – quoted as at 28 February
2025 (the date of the Company's last financial
statements)
220,820,137
Shares to be issued under the Placement
8,571,429
Shares to be issued under the Offer
100,000
Total Shares
2.3
229,491,566
Options / Performance rights issued by the Company
Unquoted securities (as previously detailed in Company ASX announcements)
ASX security code and description
2.4
Total number of
securities on issue
LISTED OPT @ $0.06 EXP 22/03/2027
92,951,732
UNL OPTIONS EXP 07/06/2025 @ $0.16
16,375,097
UNL OPTIONS EXP 31/08/2025 @ $0.16
286,460
UNL OPTIONS EXP 23/11/2025 @ $0.16
190,973
Long Term Performance Rights
1,520,793
Potential effect on control of the Company
If fully subscribed, the Offer will not have a material effect on the control of the Company.
6
2.5
Market price of Shares
The highest and lowest closing market prices of the Shares on ASX during the 3 months of trading
preceding the date of lodgement of this Prospectus with ASIC and the respective dates of those
sales, are:
Highest:
Lowest:
2.6
$0.032 on 28 March 2025
$0.012 on 26 May 2025
Details of Substantial Shareholders
Based on publicly available information as at 30 May 2025 the following is the top 10 shareholders
in the Company:
Shareholder
No of Shares
%
FREEDOM TRADER PTY LTD
14,692,194
6.65%
MR STUART RESECK & MRS NICOLE DEANNE
RESECK <RESECK SUPER FUND A/C>
13,333,334
6.04%
CUTTER SUPER PTY LTD <CUTTER SF A/C>
12,500,000
5.66%
HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED
10,045,842
4.55%
CG NOMINEES (AUSTRALIA) PTY LTD
9,574,074
4.34%
UBS NOMINEES PTY LTD
7,838,694
3.55%
10 BOLIVIANOS PTY LTD
7,768,611
3.55%
AUSUM PTY LTD <THE WORTHY A/C>
4,256,887
1.93%
ROSEDALE SUPER PTY LTD <ROSEDALE SUPER
FUND A/C>
3,000,000
1.36%
CITICORP NOMINEES PTY LIMITED
2,434,763
1.10%
7
3.
Risk factors
Investors should consider the investment in the context of their individual risk profile for
speculative investments, investment objectives and individual financial circumstances. Each
Shareholder should consult their own stockbroker, solicitor, accountant or other professional
adviser before deciding whether or not to invest in the Offer.
An investment in New Shares should be regarded as very speculative and involves many
risks. The New Shares carry no guarantee with respect to the payment of dividends, returns
of capital or the market value of those Shares.
If any of the following risks actually occurs, our business, prospects, financial condition and
results of operations could be materially and adversely affected, the trading price of the
Shares could decline and you could lose all or part of your investment.
3.1
Speculative nature of investment
This section 3 identifies some (but not all) of the major risks associated with an investment in
the Company. There may be other risks which the Directors and/or management of the
Company are unaware which may impact upon the Company, its operations and/or the value
and performance of the Shares and the Company generally. This is not an exhaustive list of
the relevant risks and the risks set out below are not in order of importance. Many of the risks
below are outside the control of the Company and its directors. These risks and other risks
not specifically referred to below, may in the future materially adversely affect the value of the
Company's shares and their performance.
An investment in Shares should be regarded as very speculative and involves many risks.
The Shares carry no guarantee with respect to the payment of dividends, returns of capital or
the market value of those securities.
Intending Applicants should carefully consider and evaluate the Company, its assets and its
business and whether the Company's Shares are suitable to acquire having regard to their
own investment objectives and financial circumstances and taking into consideration the
material risk factors, as set out below. Applicants should also read the Company's prior
continuous disclosure announcement to the ASX market in order to fully appreciate the risks
particular to an investment in the Company and in particular the risks faced by the Company
in the continued development and proposed commercialisation of its intellectual property
rights.
Any potential investor should be aware that subscribing for New Shares involves various
risks. The New Shares to be issued carry no guarantee with respect to the payment of
dividends, returns of capital or the market value of those shares.
3.2
Business risks associated with the Company
Sufficiency of funding: The Company has limited financial resources and will need to raise
additional funds from time to time to finance the continued development, sale and distribution
of its products. The directors of EXL regularly monitor the EXL Group’s cash position on an
ongoing basis and continue to explore debt and capital markets funding to support the going
concern and working capital requirements associated with EXL’s revenue base.
Agricultural risk and climate change risk: EXL is exposed to agricultural risk as the
business is reliant on agricultural products. As such, the business is subject to the risks
inherent in the agriculture industry. These risks include insects, plant diseases, storm, fire,
frost, flood, water availability, water salinity, pests, bird damage and force majeure events.
These risks may impact the financial performance through increased costs (from low yields
or increased prices from low supply) or lack of supply to address customer demands.
8
Supplier arrangements: EXL has arrangements with a number of key suppliers. To the
extent that EXL Group entities cannot secure and retain key suppliers, their respective
abilities to maintain consistent production levels may be compromised, which in turn may
have an adverse impact on the financial performance and position of EXL.
Risk of adverse events, product liability or other safety issues: As with all food or
nutraceutical products, there is a risk that the products sold by EXL could cause serious or
unexpected side effects, including risk or injury to consumers. Should any of EXL’s products
be associated with safety risks such as misuse or abuse, inadvertent mislabelling, tampering
by unauthorised third parties, or product contamination or spoilage, several materially
adverse outcomes could occur, including:
»
Regulatory authorities may revoke any approvals that have been granted, impose
more onerous facility standards or product labelling requirements, or force EXL to
conduct a product recall;
»
EXL could be subject to regulatory action or be sued and held liable for any harm
caused to customers; or
»
EXL’s brands and reputation could be damaged.
These may all impact the financial performance of the EXL Group.
Systems, security and data privacy: While EXL has policies and procedures in place to
address system security and data risks, there is a risk that these may not be adequate, which
could adversely affect EXL’s reputation and financial position. There is also a risk that
systems are not scalable or have the ability to leverage the synergies of the different
businesses across the EXL Group. This may lead to a financial impact and loss in revenue
and profitability.
Key management personnel and employees: EXL relies upon its ability to attract and retain
experienced and high performing executives and other employees. The failure to achieve this
may impact upon EXL’s ability to develop and meet its strategies, and may lead to a loss in
revenue and profitability.
Change to laws or regulations: EXL Group’s operations are highly regulated and could be
adversely affected by changes in laws, regulations or regulatory policy in the jurisdictions in
which it operates. The operations and proposed operations of EXL Group are subject to a
variety of laws, regulations and guidelines related to the retail sale of hemp-derived products.
The hemp-derived CBD industry is evolving globally, including in the USA and in Europe and
the United Kingdom. It is likely that governments worldwide will continue to explore the
benefits, risks and operations of companies involved in the hemp sector. EXL Group’s
business, prospects, reputation, performance and financial condition could all be affected by
changes to law and regulation, changes to policies, and changes in the supervisory activities
and expectations of its regulators across all of the jurisdictions in which it operates. In
particular, the regulation of hemp is developing and, as a result, a change in government or
increase in political lobbying may result in a change in government policy and an amendment
of legislation and/or regulation. For example, there is a risk that the allowable levels of THC
in hemp products sold in the US may change. This could potentially result in additional
processing costs and impact the overall financial performance of EXL Group. There is a
further risk that the US Food and Drug Administration (FDA), the regulator which regulates
ingestible and topical products including CBD products, may seek to change the laws and
regulations governing the manufacturing and marketing of CBD products in the US. This could
include current ‘good manufacturing practice’ regulation, nutrition and allergen labelling, and
label claim regulations and safety requirements including, as applicable, ‘new dietary
ingredient’ and ‘generally recognised as safe’ regulations. In the US, given that many of the
applicable laws and regulations are determined at the State level, there is also a risk that the
regulatory regime governing the EXL Group’s US operations and distribution network
9
becomes further fragmented and difficult to comply with. The introduction of new legislation
or amendments to existing legislation by governments, or the respective interpretation of the
legal requirements, in any of the legal jurisdictions which governs the operations or
contractual obligations of EXL Group, could impact adversely on the assets, operations, and
the financial performance of the EXL group and the industry in general. Regulatory
compliance and the management of regulatory change are an important part of EXL’s
planning processes. EXL intends to continue to invest in compliance and the management
and implementation of regulatory change and, at the same time, significant management
attention and resources will be required to update existing or implement new processes to
comply with new regulations (such as obligations to provide certain data and information to
regulators) or new interpretations of existing laws or regulations. The failure of EXL to
appropriately manage and implement regulatory change, including failing to implement
effective processes to comply with new regulations, could in the future result in EXL failing to
meet a compliance obligation, and this could in turn lead to a financial impact and loss in
revenue and profitability.
Loss of key relationships: The hemp-derived CBD industry is undergoing rapid growth and
change, which has resulted in increasing consolidation and formation of strategic
relationships. It is expected that this consolidation and strategic partnering will continue.
Acquisitions or other consolidating transactions could harm EXL in a number of ways. EXL
may lose strategic relationships if third parties with whom EXL has arrangements with are
acquired by or enter into relationships with a competitor (which could cause EXL to lose
access to necessary resources). EXL’s current competitors could become stronger, or new
competitors could form from consolidations. This could cause EXL to lose access to markets
or expend greater resources in order to stay competitive. Separately, the relationship between
EXL and third parties may deteriorate organically, which may have an adverse impact on the
business of EXL Group.
Production risk: The ability for EXL Group entities to cultivate and produce products is
dependent on a number of key inputs and their related costs. These key inputs include raw
materials, electricity, water, other utilities and skilled labour. Any significant interruption or
negative change in the availability or cost of these inputs could materially impact the
production of the business and subsequently, the operating results of EXL. In particular, given
the nature of the raw materials used by each of the EXL Group entities, supply may be limited
to a single or limited number of suppliers, with access to these raw materials more competitive
than conventional ingredients. As a result, there is an enhanced risk of difficulties in securing
the required supplies, or to do so on appropriate terms.
Reputational risk: There is a risk that incidents beyond the control of EXL Group entities
could occur which would have the effect of reducing patient, medical/scientific or regulatory
confidence, or preferences for cannabis or medicinal cannabis products generally. This
reputational risk could result from incidents involving members of EXL Group or other nonrelated industry participants.
Protection of intellectual property: EXL’s success will depend on, in part, its ability to
protect its intellectual property, including its trade marks, copyright, trade secrets and knowhow. To the extent EXL fails to protect its intellectual property or infringes a third party’s
intellectual property, EXL may face increased competition from similar products, have to
cease using certain intellectual property or be liable for damages. In the event that this occurs,
there is a risk that it has a materially adverse impact on EXL’s operations, financial
performance and future prospects.
Competition risk: The industries in which the current EXL Group entities are involved is
subject to domestic and international competition. While the entities will undertake all
reasonable due diligence in their business decisions and operations, they will have no
influence or control over the activities or actions of their competitors, which activities or actions
may, positively or negatively, affect the operating and financial performance of EXL. Some of
10
EXL’s competitors and potential competitors may have significantly more financial resources
and marketing experience than EXL which may lead to reduced margins and loss of revenue
or loss of market share for EXL. Further, EXL revenues in the future may be reduced as the
industry consolidates and seeks revenue accretion at the expense of profit margin.
Uncontracted sales: A material proportion of EXL’s revenue is derived from uncontracted
customer relationships, with sales made under standard terms and conditions. There is a risk
that these customer relationships may not be able to be maintained, or new relationships may
not be formed, on terms acceptable to EXL. Additionally, given the uncontracted nature of
these relationships, it is not possible to guarantee consistency of sales volumes, price or
terms going forward. EXL’s financial performance could be materially and adversely impacted
by wholesale customers:
»
materially changing their trading terms;
»
promoting the products of one or more of EXL’s competitors; or
»
refusing to promote or stock EXL’s products or significantly reducing orders for its
products.
Contracts and agreements: There are a number of risks associated with EXL’s existing
contracts and agreements, including those related to previous supply arrangements and
property leases. There is a risk that EXL’s existing contracts may be terminated, lost or
impaired, or renewed on less favourable terms. Some of EXL’s contracts can be terminated
without cause or on short notice periods (depending on events and circumstances), and
although the relevant parties may continue to operate on existing commercial terms, a
number of its existing contracts have expired or will shortly expire. A loss of any of EXL’s
contracts could have an adverse effect on its business, operating and financial performance.
Similarly, there is a risk that EXL may not meet its existing obligations under current contracts
and agreements. Should this be the case, EXL may be liable (to varying extents) under
indemnity provisions in a number of contract and agreements. Any failure to meet these
obligations could adversely impact the financial position of EXL.
Counterparty risks: EXL has entered, and may enter, into several commercial agreements
and arrangements (including licences) with third parties that are, or could be, material to the
financial performance and prospects of its business. There is a risk that counterparties may
not execute such agreements or, in respect of agreements that have been executed or are
executed in the future, the counterparty may fail to meet their obligations under those
agreements and arrangements. Negative commercial consequences will, or are likely to,
result from the non-execution of such an agreement or any non-observance of obligations
under such agreements. These consequences may include preventing the relevant EXL
Group entity from executing a part, or parts, of its business plan. This in turn may result in an
adverse effect on EXL’s proposed activities and operations, financial performance and
prospects.
Stock Market Volatility: The price of Shares may rise or fall depending upon a range of
factors beyond the Company's control and which are unrelated to the Company's operational
performance. No assurances can be made that the Company’s market performance will not
be adversely affected by any such market fluctuations or factors. Investors who decide to sell
their New Shares after the Company's capital raising may not receive the entire amount of
their original investment. The price of Shares listed on ASX may also be affected by multiple
factors including the Company's financial performance and by changes in the business
environment. The New Shares carry no guarantee in respect of profitability, dividends, return
on capital, or the price at which they may trade on the ASX. No guarantee can be given that
the Company’s share price will be greater than the issue p
Share your feedback
Discover